Novartis Releases Phase 3 Data for Zessly, Erelzi Biosimilars
June 15 2018 - 02:12AM
Dow Jones News
By Nathan Allen
Novartis AG's (NOVN.EB) Sandoz subsidiary said Friday it has
presented positive data from two phase 3 studies of its Zessly and
Erelzi biosimilars.
Results from the two studies show the drugs, which are used to
treat rheumatoid arthritis, matched their reference medicine in
terms of safety, efficacy and quality, Novartis said.
The research suggests that switching from the reference medicine
to either of the biosimilars has no negative effects on safety or
efficacy and doesn't damage the patient's ability to generate an
immune response, Novartis said.
The European Union approved Zessly for use in Europe in May,
while Erelzi received approval last June.
Write to Nathan Allen at nathan.allen@dowjones.com
(END) Dow Jones Newswires
June 15, 2018 01:57 ET (05:57 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2023 to Mar 2024